ClinicalTrials.gg
RecruitingNCT04704115ENDOKYSTEUpdated Dec 23, 2025

The Therapy of Large Endometrioma

An observational study in Endometrioma and Endometriosis Ovary, sponsored by University Hospital, Lille. Recruiting at 1 site in France. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by University Hospital, Lille · Observational

How we know

From the registry’s dates

  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
62
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 128 studies in Endometriosis with a site in France — 51 open to participants now, 56 under way, 1 of them phase 3. Endometriosis · France.

Planned enrollment
40th of 58
62 · median 133
Started
2021
with 11 others
Observational
58 of 128
23 open now
Primary completion
2026-12
later than 17 of 55 live
Registered
56th of 128
by date
Lead sponsor
9 of 128
University Hospital, Lille

Among the 128 studies in Endometriosis with a site in France, this one is the 40th largest by planned enrollment of the 58 observational ones that give a count, is one of 12 that started in 2021, is one of 58 observational ones, reaches primary completion later than 17 of the 55 other live ones, and was the 56th registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

51 of the 128 studies in Endometriosis with a site in France are open now. Recruiting first, the newest first:

46 more — sign in →

All 51 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 128 studies in Endometriosis with a site in France, or all of them as a file.
02

Study summary

Endometrioma's prevalence is between 23 and 55%. It causes pelvic pain, decrease fertility and ovarian reserve.

Currently, there's no recommendation about large endometrioma's treatment and there's no information on the best treatment to limit recurrences, preserve fertility and ovarian reserve.

In Lille university hospital, simple laparoscopic drainage associated with hormonal therapy is practiced to reduce the risk of cystectomy.

This protocol will be evaluated with an observational and prospective study, including women of childbearing age having endometrioma measuring 6 cm or above.

The aim of this study is to assess if cyst drainage associated with GnRH agonist, could decrease endometrioma recurrences, deleterious effect on ovarian reserve and evaluate impact on anti-mullerian hormone

03

Conditions studied

  • Endometrioma
  • Endometriosis Ovary

Keywords

  • Endometriomas measuring 6 cm or more
  • Ovarian Endometrioma
  • laparoscopic drainage
  • recurrence
  • AMH
  • GnRH agonist therapy
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Women presenting at a surgical consultation for the management of an endometrioma of 6cm or more

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Endometrioma size ≥ 6cm determined by MRI or ultrasonography
  • Women with isolated endometrioma or other extraovarian endometriosis: peritoneal, infiltrating endometriotic lesions and adenomyosis.
  • Cyst single or bilateral

Exclusion criteria

Exclusion Criteria:

  • Cyst with radiographic or macroscopic in laparoscopy atypia
  • Pregnancy
  • Patient with to GnRH agonist (Enantone® 3,75 mg et Decapeptyl® 3 mg)
  • Patient with contraindication to laparoscopy
  • Patient with contraindication to general anesthesia
  • Subject refusing to participate in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
62 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Rate of Recurrence of cyst ≥ 3 cm determined by MRI or pelvic ultrasonography (US)

    Time frame: at 3 months

Secondary outcomes

  1. The impact of the ovarian reserve postoperative

    Compare the dosages of anti-mullerian hormone (AMH) preoperative and postoperative at 3 months

    Time frame: at 3 months

  2. The number of re-operation

    Time frame: at 4 months

07

Study locations

1 of 1 sites recruiting
  • Hop Jeanne de Flandre Chu Lille
    Lisle-sur-Tarn, 59037, France
    Recruiting
    • · Contact0320445962
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Dec 2026, 71 months after the start.

Of 158 non-industry observational studies under Endometriosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 71 months is above that.

Counting every sponsor, half of 185 studies reached it within 30 months; a quarter within 14 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2021
First posted
Jan 11, 2021
StartActual
Jan 21, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04704115
Responsible party
Sponsor
First posted
Jan 11, 2021
Start date
Jan 21, 2021
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Dec 23, 2025

Study contacts

Chrytèle RUBOD, MD,PhD
Contact
chrystele.rubod@chru-lille.fr
0320445962 ext. +33
Chrytèle RUBOD, MD,PhD
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion